Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DNK333 twice daily · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DNK333 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DNK333 100 mg twice daily | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Mild to moderate COPD * Forced expiratory volume in 1 second (FEV1) ≥30% predicted * FEV1/FVC (forced vital capacity) \<70% * Significant amount of cough and minimal amount of sputum production, both as judged by self reporting Exclusion criteria: * Upper or lower airway inf...
DNK333 is an investigational small molecule being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is administered twice daily and is currently in Phase 1 clinical development. The drug is being evaluated for its efficacy in patients with COPD and cough.
DNK333 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development for the treatment of Chronic Obstructive Pulmonary Disease.
DNK333 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Chronic Obstructive Pulmonary Disease, with one completed Phase 1 clinical trial.
DNK333 has one completed clinical trial registered under NCT01287325, titled "Efficacy of DNK333 in Patients With COPD and Cough." This Phase 1 study enrolled 28 participants with Chronic Obstructive Pulmonary Disease and was conducted in the Netherlands and the United Kingdom.
Yes, the clinical trial for DNK333 was a randomized, double-blind, placebo-controlled study. This design helps evaluate the drug's efficacy and safety compared to a placebo in patients with Chronic Obstructive Pulmonary Disease and cough.
DNK333 is an investigational small molecule in Phase 1 clinical development for Chronic Obstructive Pulmonary Disease. It has completed one clinical trial with 28 participants, and the drug remains under investigation. It is not yet approved for any use.